The sodium pump could constitute a new target to combat glioblastomas;La pompe à sodium pourrait représenter une nouvelle cible pour le traitement des glioblastomes

Bulletin du Cancer

Volumn 95, Issue 3, 2008, Pages 271-281

  Lefranc, Florence ^a,c   Mijatovic, Tatjana ^c   Kiss, Robert ^b  

^a ERASME HOSPITAL   (Belgium)

^b Institut de Pharmacie   (Belgium)

^c Unibioscreen SA   (Belgium)

Author keywords

Actin cytoskeleton; Autophagy; Glioma; Migration; Sodium pump; Temozolomide

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); DIGOXIN; LOMUSTINE; PROCARBAZINE; TEMOZOLOMIDE; VINCRISTINE;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; AUTOPHAGY; BRAIN NEOPLASMS; CALOTROPIS; CARDENOLIDES; CELL MOVEMENT; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DACARBAZINE; DRUG SCREENING ASSAYS, ANTITUMOR; GLIOBLASTOMA; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 42149145554     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2008.0597     Document Type: Review

References (46)

1. Kleihues P, Cavenee WK. Pathology and genetics of tumours of the nervous system. International Agency for Research on Cancer (IARC) and WHO Health Organisation. Oxford, UK : Oxford Press, 2000.
2. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas : special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005 ; 23 : 2411-22.
3. Lefranc F, Sadeghi N, Camby I, Metens T, Dewitte O, Kiss R. Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther 2006 ; 6 : 719-32.
4. Laws ER, Parney IF, Huang W, et al. Glioma Outcomes Investigators. Survival following surgery and prognostic factors for recently diagnosed malignant glioma : data from the Glioma Outcomes Project. J Neurosurg 2003 ; 99 : 467-73.
5. Chang SM, Parney IF, Huang W, et al. Glioma Outcomes Project Investigators. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005 ; 293 : 557-64.
6. Laperriere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults : a systematic review. Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiother Oncol 2002 ; 64 : 259-73.
7. Stupp R, Hegi ME, van den Bent MJ, et al. Changing the paradigms- an update on the multidisciplinary management of malignant glioma. Oncologist 2006 ; 11 : 165-80.
8. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups ; National Cancer Institute of Canada Clinical Trials Group : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005 ; 352 : 987-96.
9. Hegi ME, Diserens AC, Godard S, et al. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 2004 ; 10 : 1871-4.
10. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004 ; 11 : 448-57.
11. Kondo Y, Kanzawa T, Sawaya R, Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005 ; 5 : 726-34.
12. Ogier-Denis E, Codogno P. Autophagy : a barrier or an adaptive response to cancer. Biochim Biophys Acta 2003 ; 1603 : 113-28.
13. Decaestecker C, Debeir O, Van Ham P, Kiss R. Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev 2007 ; 27 : 149-76.
14. Chakravarti A, Zhai G, Suzuki Y, et al. The prognostic significance of phosphatidylinositol-3-kinase pathway activation in human gliomas. J Clin Oncol 2004 ; 22 : 1926-33.
15. Joy AM, Beaudry CE, Tran NL, et al. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 2003 ; 116 : 4409-17.
16. Shingu T, Yamada K, Hara N, et al. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 2003 ; 63 : 4044-7.
17. Aggarwal BB. Nuclear factor-kappaB : the enemy within. Cancer Cell 2004 ; 6 : 203-8.
18. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004 ; 4 : 335-48.
19. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004 ; 4 : 592-603.
20. Lefranc F, Kiss R. Autophagy, the Troyan Horse to combat glioblastomas. Neurosurg Focus 2006 ; 20 : E7.
21. Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA 2000 ; 19 : 14376-81.
22. Pattringre S, Levine B. Bcl-2 inhibition of autophagy : a new route to cancer? Cancer Res 2006 ; 66 : 2885-8.
23. Roos WP, Batista LFZ, Naumann SC, Wick W, Weller M, Menck CFM, et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 2007 ; 26 : 186-97.
24. Joseph B, Darro F, Behard A, et al. 3-Aryl-2-quinolone derivatives : synthesis and characterization of in vitro and in vivo antitumor effects with emphasis on a new therapeutical target connected with cell migration. J Med Chem 2002 ; 45 : 2543-55.
25. Lefranc F, Mijatovic T, Mathieu V, et al. Characterization of gastrin-induced proangiogenic effects in vivo in orthotopic U373 experimental human glioblastomas and in vitro in human umbilical vein endothelial cells. Clin Cancer Res 2004 ; 10 : 8250-65.
26. Lefranc F, James S, Camby I, et al. Combined cimetidine and temozolomide, compared with temozolomide alone : significant increases in survival in nude mice bearing U373 human glioblastoma multiforme orthopic xenografts. J Neurosurg 2005 ; 102 : 706-14.
27. Lefranc F, Yeaton P, Brotchi J, Kiss R. Cimetidine, an unexpected antitumor agent, and its potential for the treatment of glioblastoma. Int J Oncol 2006 ; 28 : 1021-30.
28. Xie Z, Askari A. Na (+)/K (+)-ATPase as a signal transducer. Eur J Biochem 2002 ; 269 : 2434-9.
29. Blanco G. NaK-ATPase subunit heterogeneity as a mechanism for tissue-specific ion regulation. Semin Neprol 2005 ; 25 : 292-303.
30. Stenkwist B. Cardenolides and cancer. Anticancer Drugs 2001 ; 12 : 635-6.
31. McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA. Cardiac glycosides stimulates Ca2+ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinomas cells. Cancer Res 2000 ; 60 : 3807-12.
32. Huang YT, Chueh SC, Teng CM, Guh JH. Investigation of ouabain-induced anticancer effect in human androgen-independent prostate cancer PC-3 cells. Biochem Pharmacol 2004 ; 67 : 727-33.
33. Mijatovic T, Van Quaquebeke E, Delest B, Debeir O, Darro F, Kiss R. Cardiotonic steroids on the road to anti-cancer therapy. BBA-Reviews on Cancer 2007 ; 1776 : 32-57.
34. Van Quaquebeke E, Simon G, Andre A, et al. Identification of a novel cardenolide (2″-oxovoruscharin) from Calotropis procera and the hemisynthesis of novel derivatives displaying potent in vitro antitumor activities and high in vivo tolerance : structure-activity relationship analyses. J Med Chem 2005 ; 48 : 849-56.
35. Xie Z, Cai T. Na+-K+-ATPase-mediated signal transduction : from prorein interaction to cellular function. Mol Interv 2003 ; 3 : 157-68.
36. Barwe SP, Anilkumar G, Moon SY, et al. Novel role for Na, K-ATPase in phosphatidylinositol 3-kinase signaling and suppression of cell motility. Mol Biol Cell 2005 ; 16 : 1082-94.
37. Senner V, Schmidtpeter S, Braune S, et al. AMOG/beta2 and glioma invasion : does loss of AMOG make tumour cells run amok? Neuropathol Appl Neurobiol 2003 ; 29 : 370-7.
38. Navarro A, Anand-Apte B, Parat MO. A role for caveolae in cell migration. FASEB J 2004 ; 18 : 1801-11.
39. Mijatovic T, Op De Beeck A, Van Quaquebeke E, et al. The cardenolide UNBS1450 is able to deactivate muclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther 2006 ; 5 : 391-9.
40. Mijatovic T, Mathieu V, Gaussin JF, et al. Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia 2006 ; 8 : 402-12.
41. Mijatovic T, Roland I, Van Quaquebeke E, et al. The 1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. J Pathol 2007 ; 212 : 170-9.
42. Lefranc F, Mijatovic T, Camby I, Gailly P, Van Quaquebeke E, Darro F, et al. The binding of the UNBS1450 cardenolide to the sodium pump in human glioblastoma (GBM) cells dramatically impairs both their migration and proliferation properties. American Association for Cancer research (AACR) Annual Meeting, Washington DC, USA. April 1-5, 2006.
43. Lefranc F, Mijatovic T, Kondo Y, et al. Decreasing the sodium pump activity in glioblastoma cells induces autophagy and disorganizes their actin cytoskeleton with a resulting survival benefit in a pre-clinical model of glioblastoma. Neurosurgery 2008.
44. Belot N, Rorive S, Doyen I, et al. The molecular characterization of cell-substratum attachments in human glial tumors relates to prognostic features. Glia 2001 ; 36 : 375-90.
45. Lefranc F, Sadeghi N, Metens T, Brotchi J, Salmon I, Kiss R. Characterization of gastrin-induced cytostatic effect on cell proliferation in experimental malignant gliomas. Neurosurgery 2003 ; 52 : 881-90.
46. Branle F, Lefranc F, Camby I, et al. Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer 2002 ; 95 : 641-55.